tiprankstipranks
Divi's Laboratories Limited (IN:DIVISLAB)
:DIVISLAB
India Market
DIVISLAB
Divi's Laboratories Limited
RESEARCH TOOLSreports
Want to see IN:DIVISLAB full AI Analyst Report?

Divi's Laboratories Limited (DIVISLAB) Stock Forecast & Price Target

7 Followers
See the Price Targets and Ratings of:

DIVISLAB Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Divi's
Laboratories Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DIVISLAB Stock 12 Month Forecast

Average Price Target

₹7,717.50
▲(16.88% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Divi's Laboratories Limited in the last 3 months. The average price target is ₹7,717.50 with a high forecast of ₹8,035.00 and a low forecast of ₹7,400.00. The average price target represents a 16.88% change from the last price of ₹6,603.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5709":"₹5,709","8036":"₹8,036","6290.75":"₹6,290.8","6872.5":"₹6,872.5","7454.25":"₹7,454.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8035,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7717.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹7K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5709,6290.75,6872.5,7454.25,8036],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6551.8,6665.892307692307,6779.984615384616,6894.076923076923,7008.169230769231,7122.261538461538,7236.3538461538465,7350.446153846154,7464.538461538462,7578.630769230769,7692.723076923077,7806.815384615385,7920.907692307692,{"y":8035,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6551.8,6641.469230769231,6731.138461538461,6820.807692307692,6910.476923076923,7000.1461538461535,7089.815384615385,7179.484615384616,7269.153846153846,7358.823076923077,7448.492307692308,7538.161538461538,7627.830769230769,{"y":7717.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6551.8,6617.046153846154,6682.292307692308,6747.538461538462,6812.784615384616,6878.03076923077,6943.276923076923,7008.523076923077,7073.7692307692305,7139.015384615384,7204.261538461538,7269.507692307692,7334.753846153846,{"y":7400,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6508.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6819.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6359,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6091.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5710.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6746.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6422.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6342.6,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5960.3,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6403.35,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5906.95,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6505.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6551.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target₹8,035Average Price Target₹7,718Lowest Price Target₹7,400
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on IN:DIVISLAB
Shyam Srinivasan
Goldman Sachs
Goldman Sachs
₹8,035
Buy
21.69%
Upside
Upgraded
05/29/26
Goldman Sachs upgrades Divi's Laboratories Limited (DIVISLAB) to a Buy
J.P. Morgan Analyst forecast on IN:DIVISLAB
Bansi Desai
J.P. Morgan
J.P. Morgan
₹7,400
Buy
12.07%
Upside
Reiterated
05/25/26
J.P. Morgan Sticks to Its Buy Rating for Divi's Laboratories Limited (DIVISLAB)
HSBC Analyst forecast on IN:DIVISLAB
Damayanti Kerai
HSBC
HSBC
₹7,700→₹7,400
Buy
12.07%
Upside
Reiterated
10/14/25
Divi's Laboratories Limited (DIVISLAB) Gets a Buy from HSBC
Kotak Mahindra Analyst forecast on IN:DIVISLAB
Alankar Garude
Kotak Mahindra
Kotak Mahindra
₹5,400
Sell
-18.22%
Downside
Reiterated
09/29/25
Kotak Mahindra Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)
Jefferies Analyst forecast on IN:DIVISLAB
Dhawal Khut
Jefferies
Jefferies
₹6,750→₹7,150
Buy
8.28%
Upside
Upgraded
08/25/25
Jefferies Upgrades Divi's Laboratories Ltd (DIVI:IN) to BuyJefferies analyst Dhawal Khut upgraded Divi's Laboratories Ltd (DIVI:IN) from Hold to Buy with a price target of INR7,150.00 (from INR6,750.00).
ICICI Securities Analyst forecast on IN:DIVISLAB
Abdulkader Puranwala
ICICI Securities
ICICI Securities
₹5,610→₹5,400
Sell
-18.22%
Downside
Reiterated
08/07/25
ICICI Securities Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on IN:DIVISLAB
Shyam Srinivasan
Goldman Sachs
Goldman Sachs
₹8,035
Buy
21.69%
Upside
Upgraded
05/29/26
Goldman Sachs upgrades Divi's Laboratories Limited (DIVISLAB) to a Buy
J.P. Morgan Analyst forecast on IN:DIVISLAB
Bansi Desai
J.P. Morgan
J.P. Morgan
₹7,400
Buy
12.07%
Upside
Reiterated
05/25/26
J.P. Morgan Sticks to Its Buy Rating for Divi's Laboratories Limited (DIVISLAB)
HSBC Analyst forecast on IN:DIVISLAB
Damayanti Kerai
HSBC
HSBC
₹7,700→₹7,400
Buy
12.07%
Upside
Reiterated
10/14/25
Divi's Laboratories Limited (DIVISLAB) Gets a Buy from HSBC
Kotak Mahindra Analyst forecast on IN:DIVISLAB
Alankar Garude
Kotak Mahindra
Kotak Mahindra
₹5,400
Sell
-18.22%
Downside
Reiterated
09/29/25
Kotak Mahindra Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)
Jefferies Analyst forecast on IN:DIVISLAB
Dhawal Khut
Jefferies
Jefferies
₹6,750→₹7,150
Buy
8.28%
Upside
Upgraded
08/25/25
Jefferies Upgrades Divi's Laboratories Ltd (DIVI:IN) to BuyJefferies analyst Dhawal Khut upgraded Divi's Laboratories Ltd (DIVI:IN) from Hold to Buy with a price target of INR7,150.00 (from INR6,750.00).
ICICI Securities Analyst forecast on IN:DIVISLAB
Abdulkader Puranwala
ICICI Securities
ICICI Securities
₹5,610→₹5,400
Sell
-18.22%
Downside
Reiterated
08/07/25
ICICI Securities Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Divi's Laboratories Limited

3 Months
Bansi DesaiJ.P. Morgan
Success Rate
1/2 ratings generated profit
50%
Average Return
+0.45%
Copying Bansi Desai's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.45% per trade.
1 Year
Bansi DesaiJ.P. Morgan
Success Rate
1/2 ratings generated profit
50%
Average Return
+0.75%
Copying Bansi Desai's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.75% per trade.
2 Years
Bansi DesaiJ.P. Morgan
Success Rate
1/2 ratings generated profit
50%
Average Return
+0.75%
Copying Bansi Desai's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +0.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DIVISLAB Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
2
2
In the current month, DIVISLAB has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DIVISLAB average Analyst price target in the past 3 months is 7,717.50.
Each month's total comprises the sum of three months' worth of ratings.

DIVISLAB Financial Forecast

DIVISLAB Earnings Forecast

Next quarter’s earnings estimate for DIVISLAB is ₹24.03 with a range of ₹23.00 to ₹25.64. The previous quarter’s EPS was ₹28.31. DIVISLAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.
Next quarter’s earnings estimate for DIVISLAB is ₹24.03 with a range of ₹23.00 to ₹25.64. The previous quarter’s EPS was ₹28.31. DIVISLAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.

DIVISLAB Sales Forecast

Next quarter’s sales forecast for DIVISLAB is ₹27.94B with a range of ₹27.84B to ₹28.05B. The previous quarter’s sales results were ₹28.31B. DIVISLAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.
Next quarter’s sales forecast for DIVISLAB is ₹27.94B with a range of ₹27.84B to ₹28.05B. The previous quarter’s sales results were ₹28.31B. DIVISLAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.

DIVISLAB Stock Forecast FAQ

What is IN:DIVISLAB’s average 12-month price target, according to analysts?
Based on analyst ratings, Divi's Laboratories Limited’s 12-month average price target is 7,717.50.
    What is IN:DIVISLAB’s upside potential, based on the analysts’ average price target?
    Divi's Laboratories Limited has 16.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Divi's Laboratories Limited a Buy, Sell or Hold?
          Divi's Laboratories Limited has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Divi's Laboratories Limited’s share price target?
            The average share price target for Divi's Laboratories Limited is 7,717.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹8,035.00 ,and the lowest forecast is ₹7,400.00. The average share price target represents 16.88% Increase from the current price of ₹6,603.05.
              What do analysts say about Divi's Laboratories Limited?
              Divi's Laboratories Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Divi's Laboratories Limited?
                To buy shares of IN:DIVISLAB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.